Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Deafness and Other Communication Disorders (NIDCD) |
---|---|
Information provided by: | National Institute on Deafness and Other Communication Disorders (NIDCD) |
ClinicalTrials.gov Identifier: | NCT00317850 |
The specific aim of the Gabapentin for the Relief of Idiopathic Subjective Tinnitus Trial is to assess the therapeutic benefit of Gabapentin (Neurontin®) for subjective idiopathic troublesome tinnitus. We employed a double-blind placebo-controlled randomized clinical trial design to assess the efficacy of Gabapentin. Adults, between the ages of 18 and 70 with idiopathic, subjective, troublesome, unilateral or bilateral, non-pulsatile tinnitus of 6 month’s duration or greater and score of 38 or greater on the Tinnitus Handicap Inventory were enrolled.
Condition | Intervention | Phase |
---|---|---|
Tinnitus |
Drug: Gabapentin (Neurontin) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Gabapentin for the Relief of Idiopathic Subjective Tinnitus |
Estimated Enrollment: | 160 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | February 2006 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | R01 DC006253-01 |
Study First Received: | April 21, 2006 |
Last Updated: | May 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00317850 |
Health Authority: | United States: Federal Government |
Excitatory Amino Acids Calcium, Dietary Signs and Symptoms Sensation Disorders Hearing Disorders |
Otorhinolaryngologic Diseases Gabapentin Neurologic Manifestations Ear Diseases Tinnitus |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Antiparkinson Agents Calcium Channel Blockers Excitatory Amino Acid Agents Cardiovascular Agents |
Antimanic Agents Pharmacologic Actions Membrane Transport Modulators Sensory System Agents Therapeutic Uses Anti-Anxiety Agents Analgesics Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants Excitatory Amino Acid Antagonists |